Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-10-Speech-1-239-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-10"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance (amendment of Directive 2001/83/EC) - Pharmacovigilance (amendment of Regulation (EC) No 726/2004) (debate)2
dcterms:Language	"pt"^^xsd:language2
lpv:document identification number	"en.20120910.29.1-239-000"2
lpv:hasSubsequent	lp_eu:2012-09-10-Speech-1-240-0002
lpv:speaker	lp:Marisa Matias2
lpv:spokenAs	member; ITRE (2012-01-19--2014-06-30)3 substitute; Delegation for relations with South Africa (2009-09-16--2014-06-30)3 member_of_the_bureau; EUL/NGL (2012-01-23--2014-06-30)3 unknown; Bloco de Esquerda (2009-07-14--2014-06-30)3 substitute; Delegation for relations with the Palestinian Legislative Council (2009-09-16--2014-06-30)3 vice-chair; Delegation for relations with the Mashreq countries (2009-09-17--2014-06-30)3 substitute; ECON (2012-05-10--2014-06-30)3
lpv:translated text	"Madam President, I would also like to add my voice to the comments made by my fellow Members with regard to the report by Ms McAvan, which was an excellent piece of work. Today, we can say that European patients are much safer with this new amendment to the legislation and the regulation, and that patient protection is indeed one of our priorities. In view of all this, as I do not want to repeat what has already been said, and because I support the comments in their entirety, I would just like to mention a couple of things that occurred to me during this discussion. The first relates to the fact that the economic crisis is causing setbacks in the areas of health care and public health. Therefore, in order to make the most of your presence here, Commissioner, I would also like to draw attention to the fact that we cannot allow the economic crisis to prevent the package comprising the three pieces of legislation relating to medicines, including pharmacovigilance, counterfeit medicines and information given to patients, from being put on the waiting list, using the crisis as an excuse for failing to grant patients access to all the care, information and medicines to which they should be entitled. Neither can we in any way accept that this should be the case! A second point occurred to me during this discussion: in 2010, we voted at the first reading of the directive, but here we are in 2012 and I see that we have actually gone backwards, as now we are talking about the quality of the medicines. Today, in 2012, what might have been a rare case in 2010 has become an epidemic, and people are dying in Portugal and Greece due to lack of access to medicines. This problem is not caused by the pharmaceutical laboratories, but by this laboratory here. I sincerely hope that we succeed in addressing these problems, as medicines represent advances in public health and health care, and we cannot ignore these problems, which touch upon a vital part of people’s lives."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph